Biochemical analysis reveals carbapenemase activity and poor clavulanate inhibition in Mycobacterium abscessus beta-lactamases, indicating rising risks of broad-spectrum antibiotic resistance.
The objectives of this study were to determine the kinetic parameters of purified recombinant Bla Mab and Bla Mmas by spectrophotometry, analyze the genetic environment of the bla Mab and bla Mmas genes in both species by polymerase chain reaction and sequencing, furthermore, in silico models of both enzymes in complex with imipenem were obtained by modeling tools. Our results showed that Bla Mab and Bla Mmas have a similar hydrolysis behavior, displaying high catalytic efficiencies toward penams, cephalothin, and nitrocefin; none of the enzymes are well inhibited by clavulanate. Bla Mmas hydrolyzes imipenem at higher efficiency than cefotaxime and aztreonam. Bla Mab and Bla Mmas showed that their closest structural homologs are KPC-2 and SFC-1, which correlate to the mild carbapenemase activity toward imipenem observed at least for BlaMmas. They also seem to differ from other class A β-lactamases by the presence of a more flexible Ω loop, which could impact in the hydrolysis efficiency against some antibiotics. A −35 consensus sequence (TCGACA) and embedded at the 3′ end of MAB_2874, which may constitute the bla Mab and bla Mmas promoter. Our results suggest that the resistance mechanisms in fast-growing mycobacteria could be probably evolving toward the production of β-lactamases that have improved catalytic efficiencies against some of the drugs commonly used for the treatment of mycobacterial infections, endangering the use of important drugs like the carbapenems.
No takes yet. Share an insight, caveat, or question.
Ramírez et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: